The Readout Loud
Episode 168: Aduhelm's latest twist, & how Covid variants are shaping the summer
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
First, we discuss the latest twists following the FDA's widely condemned decision to approve Aduhelm, Biogen's treatment for Alzheimer's disease. Then, our STAT colleague Helen Branswell joins us to talk about whether viral variants are going to stymie the U.S.'s summer reopening. Finally, STAT's Mario Aguilar calls in to break down the record-setting sums going into digital health companies in 2021.